

# Anteris Technologies Ltd

19:25 06 Mar 2018

## Admedus secures regulatory approval in Canada for heart tissue products

Admedus Ltd (ASX:AHZ) has received regulatory approval to introduce its CardioCel 3D® and VascuCel® products in Canada, alongside CardioCel® which is already available.

CardioCel 3D is a shaped tissue product representing a disruptive technology in the high-complexity congenital defect repair space.

### WATCH: Admedus Ltd moving up the value chain and preparing for 'pivotal' year

Wayne Paterson, chief executive officer, said: "We welcome today's announcement and are pleased to be able to expand our product offering in Canada, giving physicians and patients access to the numerous health benefits of our latest clinically-superior technology.

"This opportunity presents Admedus with a valuable opportunity to move up the value chain and increase our presence and market share in North America."

### Unique product mimics the characteristics of normal human tissue

CardioCel 3D offers patients the long-term health benefits of Admedus' ADAPT® technology.

ADAPT treated tissue has been proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth.

CardioCel 3D's pre-shaped curve provides physicians access to an optimised arch reconstruction solution with non-antigenic response and unique calcification resistance.

### CardioCel 3D and VascuCel are already sold in the U.S.

CardioCel 3D is the latest product from Admedus' proprietary ADAPT portfolio and was officially launched in the U.S. on 1 February 2018.

Canada is the second market to have access to this technology.

Admedus' VascuCel scaffold is also bioengineered using the ADAPT technology and provides enhanced procedural efficiency for a broad spectrum of vascular surgical procedures.

### READ: Admedus introduces heart tissue technology to India

**Price:** 4

**Market Cap:** \$23.64 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** AVR

**Listing:** ASX

**52 week High Low**  
7.5 3.03

**Sector:** Pharma & Biotech

**Website:** anteristech.com

#### Company Synopsis:

*Anteris Technologies Ltd (ASX:AVR) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients.*

action@proactiveinvestors.com

The company recently introduced its ADAPT engineered tissue technology to India, a country with circa 50 million cardiac patients and 280,000 babies born annually with a congenital heart defect.

ADAPT achieved sales revenue of \$2.1 million for the December 2017 quarter, up 18% on the previous quarter, largely driven by increased sales in the European and emerging markets regions.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).